-

Splitting done into:
# Response to EGFR TKIs: Confers increased sensitivity
# Response to anti-EGFR antibodies: Currently no role for EGFR mutation in predicting response in NSCLC
That's all
Splitting done into:
# Response to AKT inhibitors: Unknown at this time
# Response to HER2 inhibitors (lapatinib): Unknown at this time
# Response to PI3K inhibitors: Unknown at this time
# Response to PI3K/mTOR inhibitors: Unknown at this time
# Response to anti-HER2 antibodies (trastuzumab): Unknown at this time
# Response to mTOR inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to cetuximab, panitumumab (anti-EGFR antibodies): Unlikely
# Response to erlotinib/gefitinib (EGFR TKIs): Unknown at this time. However, gefitinib monotherapy is not active in metastatic colorectal cancer (Rothenberg et al. 2005)
That's all
Splitting done into:
# Response to AKT inhibitors: Unknown at this time
# Response to PI3K inhibitors: Unknown at this time
# Response to PI3K/mTOR inhibitors: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time
# Response to mTOR inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to cetuximab, panitumumab(anti-EGFR antibodies): Unlikely
# Response to erlotinib/gefitinib (EGFR TKIs): Unknown at this time. However, gefitinib monotherapy is not active in metastatic colorectal cancer (Rothenberg et al. 2005)
That's all
Splitting done into:
# Response to cetuximab, panitumumab (anti-EGFR antibodies): Possible
# Response to erlotinib/gefitinib (EGFR TKIs): Unknown at this time. However, gefitinib monotherapy is not active in metastatic colorectal cancer (Rothenberg et al. 2005)
That's all
Splitting done into:
# Response to dasatinib: Unknown at this time. Preclinical models suggest activity
# Response to imatinib: Confers decreased sensitivity
# Response to nilotinib: Unknown at this time
# Response to sorafenib: Unknown at this time
# Response to sunitinib: Confers decreased sensitivity
That's all
Splitting done into:
# Response to dasatinib: Unknown at this time
# Response to imatinib: Confers intermediate sensitivity; Higher doses of imatinib (up to 800 mg total daily dose) may be more effective in metastatic disease than 400 mg oral daily
# Response to nilotinib: Unknown at this time
# Response to sorafenib: Some evidence of activity (Ryu et al. 2011)
# Response to sunitinib: Confers increased sensitivity
That's all
Splitting done into:
# Response to dasatinib: Unknown at this time
# Response to imatinib: Confers increased sensitivity
# Response to nilotinib: Unknown at this time
# Response to sorafenib: Some evidence of activity (Kindler et al. 2011;Ryu et al. 2011)
# Response to sunitinib: Decreased sensitivity to second-line sunitinib; Too few patients have been treated in the imatinib-naive setting
That's all
Splitting done into:
# Response to dasatinib: Unknown at this time
# Response to imatinib: Confers increased sensitivity
# Response to nilotinib: Unknown at this time
# Response to sorafenib: Unknown at this time
# Response to sunitinib: Confers sensitivity in vitro
That's all
Splitting done into:
# Response to dasatinib: Unknown at this time
# Response to imatinib: Confers sensitivity as a primary mutation; Confers resistance as a secondary mutation
# Response to nilotinib: Unknown at this time
# Response to sorafenib: Unknown at this time
# Response to sunitinib: Sensitive in in vitro studies; Too few patients in imatinib naive or second-line settings to determine
That's all
Splitting done into:
# Response to dasatinib: Unknown at this time
# Response to imatinib: Confers resistance as a secondary mutation
# Response to nilotinib: Unknown at this time
# Response to sorafenib: Unknown at this time
# Response to sunitinib: Sensitive in in vitro studies; Too few patients in imatinib nave or second-line settings to determine
That's all
Splitting done into:
# Response to dasatinib: Unknown at this time
# Response to imatinib: Confers increased sensitivity in vitro
# Response to nilotinib: Unknown at this time
# Response to sorafenib: Unknown at this time
# Response to sunitinib: Unknown at this time
That's all
Splitting done into:
# Response to dasatinib: Unknown at this time
# Response to imatinib: Primary mutation sensitive in vitro; Confers resistance as a secondary mutation
# Response to nilotinib: Unknown at this time
# Response to sorafenib: Unknown at this time
# Response to sunitinib: Confers resistance as secondary mutation; Too few people treated in imatinib-nave setting to determine activity
That's all
Splitting done into:
# Response to dasatinib: Unknown at this time
# Response to imatinib: Confers increased sensitivity
# Response to nilotinib: Unknown at this time
# Response to sorafenib: Unknown at this time
# Response to sunitinib: Unknown at this time
That's all
Splitting done into:
# Response to dasatinib: Some evidence of activity (Schittenhelm et al. 2006;Trent et al. 2011)
# Response to imatinib: Confers decreased sensitivity
# Response to nilotinib: Unknown at this time
# Response to regorafenib: Evidence of activity (Demetri et al. 2013)
# Response to sorafenib: Some evidence of activity (Kindler et al. 2011)
# Response to sunitinib: Some evidence of activity
That's all
Splitting done into:
# Response to dasatinib: Unknown at this time
# Response to imatinib: Confers resistance
# Response to nilotinib: Unknown at this time
# Response to sorafenib: Unknown at this time
# Response to sunitinib: Confers resistance
# Response to vemurafenib: Unknown at this time
That's all
Splitting done into:
# Response to EGFR TKIs: Confers decreased sensitivity
# Response to anti-EGFR antibodies: Unknown at this time
That's all
Splitting done into:
# Response to EGFR TKIs: Confers decreased sensitivity
# Response to EGFR antibodies: Unknown at this time
# Response to MET TKIs: Confers increased sensitivity
# Response to MET antibodies: Unknown at this time
That's all
Splitting done into:
# Response to AKT inhibitors: Unknown at this time
# Response to EGFR TKIs: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time
That's all
Splitting done into:
# Response to EGFR TKIs: Unknown at this time
# Response to MEK inhibitors: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time
That's all
Splitting done into:
# Response to AKT inhibitors: Unknown at this time
# Response to EGFR TKIs: Unknown at this time
# Response to PI3K inhibitors: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time
# Response to dual PI3K/mTOR inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to EGFR TKIs: Confers decreased sensitivity
# Response to HSP90 inhibitors: Confers increased sensitivity
# Response to anti-EGFR antibodies: Unknown at this time
# Response to crizotinib (ALK/MET TKI): Confers decreased sensitivity
That's all
Splitting done into:
# Response to EGFR TKIs: Confers decreased sensitivity
# Response to anti-EGFR antibodies: Currently no role forEGFRmutation in predicting response in NSCLC
That's all
Splitting done into:
# Response to EGFR TKIs: Unknown at this time
# Response to HER2 TKIs: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time
# Response to anti-HER2 antibodies: Unknown at this time
That's all
Splitting done into:
# Response to ALK TKIs: Confers increased sensitivity
# Response to EGFR TKIs: Confers decreased sensitivity
# Response to HSP90 inhibitors: Confers increased sensitivity
# Response to anti-EGFR antibodies: Unknown at this time
That's all
Splitting done into:
# Response to cetuximab, panitumumab (anti-EGFR antibodies): Unknown at this time
# Response to crizotinib (ALK/MET/ROS1 TKI): Confers increased sensitivity
# Response to erlotinib/gefitinib (EGFR TKIs): Confers decreased sensitivity
That's all
Splitting done into:
# Response to BRAF inhibitors: Unknown at this time
# Response to EGFR TKIs: Unknown at this time
# Response to MEK inhibitors: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time
# Response to dasatinib: Unknown at this time
That's all
Splitting done into:
# Response to ABL/SRC/KIT inhibitor dasatinib: Unknown at this time
# Response to BRAF inhibitors: Unknown at this time
# Response to EGFR TKIs: Unknown at this time
# Response to MEK inhibitors: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time
That's all
Splitting done into:
# Response to EGFR TKIs: Unknown at this time
# Response to MEK1/2 inhibitors: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time
That's all
Splitting done into:
# Response to EGFR TKIs: Unknown at this time
# Response to MEK1/2 inhibitors: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time in NSCLC
That's all
Splitting done into:
# Response to BRAF inhibitors: Confers increased sensitivity
# Response to EGFR TKIs: Unknown at this time
# Response to MEK inhibitors: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time
# Response to dasatinib: Unknown at this time
That's all
Splitting done into:
# Response to EGFR TKIs: Confers decreased sensitivity
# Response to anti-EGFR antibodies: Currently no role for EGFR mutation in predicting response in NSCLC
That's all
Splitting done into:
# Response to BRAF inhibitors: Unknown at this time
# Response to KIT inhibitors: Unknown at this time
# Response to MEK inhibitors: Confers sensitivity
That's all
Splitting done into:
# Response to BRAF inhibitors: Unknown at this time
# Response to KIT inhibitors: Confers decreased sensitivity
# Response to MEK inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to BRAF inhibitors: Unknown at this time
# Response to KIT inhibitors: Unknown at this time
# Response to MEK inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to BRAF inhibitors: Unknown at this time
# Response to KIT inhibitors: Confers increased sensitivity
# Response to MEK inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to BRAF inhibitors: Confers increased sensitivity
# Response to KIT inhibitors: Unknown at this time
# Response to MEK inhibitors: Unknown at this time
That's all
Splitting done into:
# Imatinib (KIT inhibitor): May confer decreased sensitivity
# Sunitinib (KIT inhibitor): May confer decreased sensitivity
# Sorafenib (KIT inhibitor): Confers increased sensitivity
# Dasatinib (KIT inhibitor): May confer increased sensitivity
That's all
Splitting done into:
# Response to imatinib (KIT inhibitor): May confer sensitivity
# Response to sunitinib (KIT inhibitor): May confer increased sensitivity
That's all
Splitting done into:
# Response to dasatinib (KIT inhibitor): May confer increased sensitivity
# Response to imatinib (KIT inhibitor): May confer sensitivity
# Response to sunitinib (KIT inhibitor): May confer increased sensitivity
That's all
Splitting done into:
# Response to dasatinib (KIT inhibitor): May confer increased sensitivity
# Response to imatinib (KIT inhibitor): Confers increased sensitivity
# Response to sunitinib (KIT inhibitor): May confer increased sensitivity
That's all
Splitting done into:
# Response to mutant specific BRAF inhibitors: Unknown at this time
# Response to non-specific BRAF inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to non-specific RET TKIs: Improved PFS with vandetanib
# Response to specific RET TKIs: Unknown at this time
That's all
Splitting done into:
# Response to non-specific RET inhibitors: Improved PFS with vandetanib
# Response to specific RET-inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to mutant specific BRAF-inhibitors: Unknown at this time
# Response to non-specific BRAF inhibitors: Variable response
That's all
Splitting done into:
# Response to AKT inhibitors: Unknown at this time
# Response to PI3K inhibitors: Unknown at this time
# Response to dual PI3K/mTOR inhibitors: Unknown at this time
# Response to mTor inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to MEK inhibitors: Unknown at this time (Nakayama et al. 2008)
# Response to cetuximab, panitumumab (anti-EGFR antibodies): Unknown at this time (Haldar et al. 2007)
# Response to erlotinib/gefitinib (EGFR TKIs): Unknown at this time (Haldar et al. 2007)
That's all
Splitting done into:
# Response to BRAF inhibitors: Unknown at this time
# Response to EGFR TKIs: Unknown at this time (Haldar et al. 2007)
# Response to MEK inhibitors: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time (Haldar et al. 2007)
That's all
Splitting done into:
# Response to FGFR inhibitors: Unknown at this time
# Response to endocrine therapy: Unknown at this time
That's all
Splitting done into:
# Response to crizotinib (ALK/MET TKI):Confers decreased sensitivity
# Response to 2nd generation ALK TKIs: Variable
# Response to HSP90 inhibitors: Confers increased sensitivity
# Response to EGFR TKIs: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time
That's all
Splitting done into:
# Response to BRAF inhibitors: Unknown at this time
# Response to EGFR monoclonal antibodies: Unknown at this time
# Response to MEK inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to AKT inhibitors: Unknown at this time
# Response to EGFR TKIs: Unknown at this time
# Response to PI3K inhibitors: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time
# Response to dual FRAP/mTOR inhibitors: Unknown at this time
# Response to dual PI3K/mTOR inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to BRAF inhibitors: Unknown at this time
# Response to EGFR TKIs: Unknown at this time
# Response to MEK inhibitors: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time
That's all
Splitting done into:
# Response to AKT inhibitors: Unknown at this time
# Response to EGFR TKIs: Unknown at this time
# Response to EGFR antibodies: Unknown at this time
# Response to PI3K inhibitors: Unknown at this time
# Response to PI3K/mTOR inhibitors: Unknown at this time
# Response to mTOR inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to BRAF inhibitors: Unknown at this time
# Response to EGFR TKIs: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time
# Response to combination of BRAF and EGFR inhibitors: Unknown at this time
# Response to combination of BRAF inhibitors with other therapies: Unknown at this time
# Response to mutant-specific BRAF inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to AKT inhibitors: Unknown at this time
# Response to EGFR TKIs: Unknown at this time
# Response to PI3K inhibitors: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time
That's all
Splitting done into:
# Response to SMO inhibitors: Unknown at this time
# Response to vismodegib: Hypothesized to confer decreased sensitivity
That's all
Splitting done into:
# Response to vismodegib: Hypothesized to confer decreased sensitivity
# Other SMO inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to crizotinib: Unknown at this time
# Response to other ALK inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to JAK inhibitors: Unknown at this time
# Response to PI3K/mTOR inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to ALK inhibitors: Unknown at this time
# Response to CD30 antibodies: Unknown at this time
# Response to JAK inhibitors: Unknown at this time
# Response to PI3K/AKT/mTOR inhibitors: Unknown at this time
# Response to RAS inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to BRAF inhibitors: Unknown at this time
# Response to EGFR TKIs: Unknown at this time
# Response to MEK inhibitors: Unknown at this time
# Response to anti-EGFR antibodies: Unknown at this time
# Response to dasatinib: Confers increased sensitivity
That's all
Splitting done into:
# Response to bosutinib: Confers sensitivity
# Response to dasatinib: Confers sensitivity
# Response to imatinib: Confers sensitivity
# Response to nilotinib: Confers sensitivity
# Response to ponatinib: Confers sensitivity
That's all
Splitting done into:
# Response to imatinib:Unknown at this timea
# Response to dasatinib:Unknown at this timeb
# Response to nilotinib:Unknown at this timeb
# Response to bosutinib:Unknown at this timeb
# Response to ponatinib:Unknown at this time
That's all
Splitting done into:
# Response to bosutinib: Unknown at this time
# Response to dasatinib: Retains sensitivity
# Response to imatinib: Confers reduced sensitivity
# Response to nilotinib: Confers reduced sensitivity
# Response to ponatinib: Unknown at this time
That's all
Splitting done into:
# Response to bosutinib: Confers reduced sensitivity
# Response to dasatinib: Confers reduced sensitivity
# Response to imatinib: Confers reduced sensitivity
# Response to nilotinib: Confers reduced sensitivity
# Response to ponatinib: Retains sensitivity
That's all
Splitting done into:
# Response to bosutinib: Unknown at this time
# Response to dasatinib: Confers reduced sensitivity
# Response to imatinib: Confers reduced sensitivity
# Response to nilotinib: Retains sensitivity
# Response to ponatinib: Unknown at this time
That's all
Splitting done into:
# Response to dasatinib (KIT inhibitor): May confer increased sensitivity
# Response to imatinib (KIT inhibitor): May confer increased sensitivity
# Response to sorafenib (KIT inhibitor): May confer increased sensitivity
# Response to sunitinib (KIT inhibitor): May confer increased sensitivity
That's all
Splitting done into:
# Response to aromatase inhibitors: Unknown at this time
# Response to selective estrogen receptor modulators and antagonists: Unknown at this time
That's all
Splitting done into:
# Response to ado-trastuzumab emtansine: Confers increased sensitivity
# Response to lapatinib: Confers increased sensitivity
# Response to neratinib: Confers increased sensitivity
# Response to pertuzumab: Confers increased sensitivity
# Response to trastuzumab: Confers increased sensitivity
That's all
Splitting done into:
# Response to ado-trastuzumab emtansine: Unknown at this time
# Response to lapatinib: Unknown at this time
# Response to neratinib: Unknown at this time
# Response to pertuzumab: Unknown at this time
# Response to trastuzumab: Unknown at this time
That's all
Splitting done into:
# Response to ado-trastuzumab emtansine: Unknown at this time
# Response to gefitinib: Unknown at this time
# Response to lapatinib: Unknown at this time
# Response to neratinib: Unknown at this time
# Response to pertuzumab: Unknown at this time
# Response to trastuzumab: Unknown at this time
That's all
Splitting done into:
# Response to ado-trastuzumab emtansine: Unknown at this time
# Response to canertinib: Unknown at this time
# Response to lapatinib: Unknown at this time
# Response to neratinib: Unknown at this time
# Response to pertuzumab: Unknown at this time
# Response to trastuzumab: Unknown at this time
That's all
Splitting done into:
# Response to DOT1L inhibitors: Currently no role for RUNX1-RUNX1T1 in predicting response
# Response to FLT3 inhibitors: Currently no role for RUNX1-RUNX1T1 in predicting response
# Response to JAK2 inhibitors: Currently no role for RUNX1-RUNX1T1 in predicting response
# Response to MEK inhibitors: Currently no role for RUNX1-RUNX1T1 in predicting response
That's all
Splitting done into:
# Response to DOT1L inhibitors: Currently no role for CBFB-MYH11 in predicting response
# Response to FLT3 inhibitors: Currently no role for CBFB-MYH11 in predicting response
# Response to JAK2 inhibitors: Currently no role for CBFB-MYH11 in predicting response
# Response to MEK inhibitors: Currently no role for CBFB-MYH11 in predicting response
That's all
Splitting done into:
# Response to DOT1L inhibitors: Currently no role for PML-RARA in predicting response
# Response to FLT3 inhibitors: Currently no role for PML-RARA in predicting response
# Response to JAK2 inhibitors: Currently no role for PML-RARA in predicting response
# Response to MEK inhibitors: Currently no role for PML-RARA in predicting response
# Response to all-trans-retinoic acid and arsenic trioxide: Confers sensitivity
That's all
Splitting done into:
# Response to DOT1L inhibitors: Unknown at this time
# Response to FLT3 inhibitors: Currently no role for MLL-MLLT3 in predicting response
# Response to JAK2 inhibitors: Currently no role for MLL-MLLT3 in predicting response
# Response to MEK inhibitors: Currently no role for MLL-MLLT3 in predicting response
That's all
Splitting done into:
# Response to DOT1L inhibitors: Currently no role for DEK-NUP214 in predicting response
# Response to FLT3 inhibitors: Currently no role for DEK-NUP214 in predicting response
# Response to JAK2 inhibitors: Currently no role for DEK-NUP214 in predicting response
# Response to MEK inhibitors: Currently no role for DEK-NUP214 in predicting response
That's all
Splitting done into:
# Response to DOT1L inhibitors: Currently no role for RPN1-EVI1 in predicting response
# Response to FLT3 inhibitors: Currently no role for RPN1-EVI1 in predicting response
# Response to JAK2 inhibitors: Currently no role for RPN1-EVI1 in predicting response
# Response to MEK inhibitors: Currently no role for RPN1-EVI1 in predicting response
That's all
Splitting done into:
# Response to DOT1L inhibitors: Currently no role for RBM15-MKL1 in predicting response
# Response to FLT3 inhibitors: Currently no role for RBM15-MKL1 in predicting response
# Response to JAK2 inhibitors: Currently no role for RBM15-MKL1 in predicting response
# Response to MEK inhibitors: Currently no role for RBM15-MKL1 in predicting response
That's all
Splitting done into:
# Response to aromatase inhibitors: Confers increased sensitivity
# Response to estrogen receptor agonists/antagonists: Confers increased sensitivity
# Response to selective estrogen receptor modulators: Confers increased sensitivity
That's all
Splitting done into:
# Response to FLT3 inhibitors: Unknown at this time
# Response to JAK2 inhibitors: Unknown at this time
# Response to MEK inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to FLT3 inhibitors: Unknown at this time
# Response to JAK2 inhibitors: Unknown at this time
# Response to MEK inhibitors: Unknown at this time
# Response to sorafenib: Unknown at this time
That's all
Splitting done into:
# Response to FLT3 inhibitors: May confer increased sensitivity
# Response to JAK2 inhibitors: Unknown at this time
# Response to MEK inhibitors: Unknown at this time
# Response to sorafenib: May confer increased sensitivity
That's all
Splitting done into:
# Response to FLT3 inhibitors: Unknown at this time
# Response to JAK2 inhibitors: Unknown at this time
# Response to KIT inhibitors: Unknown at this time
# Response to MEK inhibitors: Unknown at this time
That's all
Splitting done into:
# Response to FLT3 inhibitors: Unknown at this time
# Response to JAK2 inhibitors: Unknown at this time
#